ReviewThrombosis journal2025
Cancer-associated venous thromboembolism: a comprehensive review.
Review in Thrombosis journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Rivaroxaban versus Low Molecular Weight Heparin for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisPooled it
- Endothelial indoleamine 2,3-dioxygenase 1 drives high-tryptophan diet-mediated thrombosis in cancer-bearing mice.Blood vessels, thrombosis & hemostasis · 2026Article
- Role of extended venous thromboembolism prophylaxis in patients with colorectal neoplasia who underwent minimally invasive colorectal surgery within an enhanced recovery after surgery protocol.Surgical endoscopy · 2026Article
- Bleeding in patients with lung adenocarcinoma receiving concurrent administration of anticoagulation and vascular endothelial growth factor or epidermal growth factor receptor inhibitors.Journal of thrombosis and haemostasis : JTH · 2026Article
- Systemic Immune-Inflammation Index, Thrombotic Status, and Mortality in Patients with Cancer: A Matched Cohort Study.Diseases (Basel, Switzerland) · 2026Article
- Cancer-Associated Pulmonary Embolism in Contemporary Clinical Practice: Clinical Severity, Incidental Detection, and Early Outcomes in a Real-World Cohort.Journal of clinical medicine · 2026Article
- Antithrombotic Therapy After PCI in High-Risk Cardiovascular Patients: Navigating Complexity Beyond Guidelines.Journal of clinical medicine · 2026Review
- Tranexamic Acid in Lower Extremity Endoprosthetic Reconstruction for Oncologic Indications: A Retrospective Comparative Study of 617 Patients.Journal of surgical oncology · 2026Article
- When Cancer Clots: An Extensive Radiologic Analysis of Cancer-Associated Thromboembolism.Cancers · 2026Review
- Mitochondrial IκBα fuels cancer progression through metabolic rewiring, endothelial activation, and thrombotic spread.Cell death discovery · 2026Article
- Predictive Role of Pre-Radiotherapy D-Dimer and Inflammatory Markers in Monitoring Outcomes After Treatment in Hormone-Positive Breast Cancer: A Retrospective Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
- Cancer-Associated Thrombosis in Breast Cancer: Risk Factors and Personalized Management.Journal of clinical medicine · 2026Article
- Chronic thromboembolic pulmonary hypertension: towards an etiology-oriented conceptual framework.Frontiers in medicine · 2026Review
- Cancer-Associated Arterial Thrombosis: Mechanisms and Risk Factors.Oncology research · 2026Review
- Immune checkpoint blockade and thrombo-inflammatory remodeling in microsatellite instability-high intrahepatic cholangiocarcinoma with Trousseau syndrome: a case report.Frontiers in medicine · 2026Article
- New Horizons in Venous Thromboembolism Management: A Narrative Review.Journal of clinical medicine · 2025Review
- Trousseau's Syndrome and Marantic Endocarditis in a Patient with Pulmonary Adenocarcinoma: A Case Report and a Brief Review of the Literature.Reports (MDPI) · 2025Article
- The Crucial Role of Tinzaparin in Managing Venous Thromboembolism in the Cancer Population.Journal of clinical medicine · 2025Review
- Elevated C-reactive protein and D-dimer to predict venous thromboembolism in patients with bladder cancer.Frontiers in immunology · 2025Article
- Emerging Insights of Management of Venous Thromboembolism in Patients With Cancer.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has been 200 years since the first case of cancer-associated thrombosis (CAT) was reported. Venous thromboembolism (VTE) remains a leading cause of morbidity and mortality in cancer patients. Malignant tumors interact with the coagulation system in complex ways. CAT continues to pose a significant challenge in clinical practice. The risk factors for CAT are complex and multifactorial, primarily including patient, cancer, and therapy-related factors. We have introduced assessment models for CAT and bleeding risk, but the performance of these models has been less than satisfactory. Currently, the main anticoagulant drugs for treating CAT include vitamin K antagonists (VKAs), low molecular weight heparin (LMWH), and direct oral anticoagulants (DOACs). We have provided a detailed overview of the advantages and disadvantages of these three types of drugs and suggestions on choosing the appropriate type of medication for different clinical scenarios. CAT incidence, pathophysiology, risk factors, risk prediction models, and recent advancements in treatment and management are summarized in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.